- Home
- GEG vs GRCE Comparison
GEG vs GRCE Comparison
Compare GEG & GRCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GEG
- GRCE
- Stock Information
- Founded
- GEG 1994
- GRCE 2002
- Country
- GEG United States
- GRCE United States
- Employees
- GEG N/A
- GRCE N/A
- Industry
- GEG Computer Software: Prepackaged Software
- GRCE
- Sector
- GEG Technology
- GRCE
- Exchange
- GEG Nasdaq
- GRCE NYSE
- Market Cap
- GEG 55.6M
- GRCE 45.4M
- IPO Year
- GEG N/A
- GRCE N/A
- Fundamental
- Price
- GEG $1.89
- GRCE $3.29
- Analyst Decision
- GEG
- GRCE Strong Buy
- Analyst Count
- GEG 0
- GRCE 1
- Target Price
- GEG N/A
- GRCE $12.00
- AVG Volume (30 Days)
- GEG 23.0K
- GRCE 129.9K
- Earning Date
- GEG 02-05-2025
- GRCE 02-13-2025
- Dividend Yield
- GEG N/A
- GRCE N/A
- EPS Growth
- GEG N/A
- GRCE N/A
- EPS
- GEG 0.00
- GRCE N/A
- Revenue
- GEG $19,204,000.00
- GRCE N/A
- Revenue This Year
- GEG N/A
- GRCE N/A
- Revenue Next Year
- GEG N/A
- GRCE N/A
- P/E Ratio
- GEG $17,855.18
- GRCE N/A
- Revenue Growth
- GEG 73.74
- GRCE N/A
- 52 Week Low
- GEG $1.70
- GRCE $2.13
- 52 Week High
- GEG $2.12
- GRCE $4.97
- Technical
- Relative Strength Index (RSI)
- GEG 56.81
- GRCE N/A
- Support Level
- GEG $1.79
- GRCE N/A
- Resistance Level
- GEG $1.96
- GRCE N/A
- Average True Range (ATR)
- GEG 0.05
- GRCE 0.00
- MACD
- GEG 0.00
- GRCE 0.00
- Stochastic Oscillator
- GEG 50.00
- GRCE 0.00
About GEG Great Elm Group Inc.
Great Elm Group Inc operates as an alternative asset manager focused on growing a scalable and diversified portfolio of long-duration and permanent capital vehicles across credit, real estate, specialty finance, and other alternative strategies. Along with its subsidiaries, it manages Great Elm Capital Corp, a publicly traded business development company, and Monomoy Properties REIT, LLC, an industrial-focused real estate investment trust, in addition to other investments.
About GRCE GRACE THERAPEUTICS INC
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.